This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Lev A , Lulla AR , Wagner J , Ralff MD , Kiehl JB , Zhou Y , Benes CH , Prabhu VV , Oster W , Astsaturov I , Dicker DT , El-Deiry WS
Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP
Oncotarget. 2017 Oct;8(47) :81776-81793
PMID: 29137221 PMCID: PMC5669847 URL: https://www.ncbi.nlm.nih.gov/pubmed/29137221
AbstractPancreatic cancer is chemo-resistant and metastasizes early with an overall five-year survival of similar to 8.2%. First-in-class imipridone ONC201 is a small molecule in clinical trials with anti-cancer activity. ONC212, a fluorinated-ONC201 analogue, shows preclinical efficacy in melanoma and hepatocellular-cancer models. We investigated efficacy of ONC201 and ONC212 against pancreatic cancer cell lines (N = 16 including 9 PDX-cell lines). We demonstrate ONC212 efficacy in 4 in-vivo models including ONC201-resistant tumors. ONC212 is active in pancreatic cancer as single agent or in combination with 5-fluorouracil, irinotecan, oxaliplatin or RTK inhibitor crizotinib. Based on upregulation of pro-survival IGF1-R in some tumors, we found an active combination of ONC212 with inhibitor AG1024, including in vivo. We show a rationale for targeting pancreatic cancer using ONC212 combined with targeting the unfolded-protein response and ER chaperones such as GRP78/BIP. Our results lay the foundation to test imipridones, anti-cancer agents, in pancreatic cancer, that is refractory to most drugs.
NotesLev, Avital Lulla, Amriti R. Wagner, Jessica Ralff, Marie D. Kiehl, Joshua B. Zhou, Yan Benes, Cyril H. Prabhu, Varun V. Oster, Wolfgang Astsaturov, Igor Dicker, David T. El-Deiry, Wafik S.